COMMUNIQUÉS West-GlobeNewswire

AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update
14/03/2024
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update ACI-24.060 ABATE Phase 2 trial to report Abeta-PET imaging results in Q2 and H2 ACI-7104.056 VacSYn Phase 2 trial in Parkinson’s disease [...]
Microbix’s Clot-Buster Drug Project Advances
14/03/2024
Sequel Pharma Executes Agreement with CDMO for Drug Substance Production MISSISSAUGA, Canada, March 14, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. ( TSX: MBX, OTCQX: MBXBF, Microbix ® ), a life sciences innovator [...]
Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors
14/03/2024
- IMM-1-104 has been well-tolerated, demonstrating the potential for a differentiated safety profile - - 100% suppression of acquired RAS alterations was observed in evaluable patients profiled for ctDNA and treated [...]
Tilray Medical Receives Approval for First Medical Cannabis Extract in Portugal
14/03/2024
CANTANHEDE, Portugal, March 14, 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis and consumer packaged goods company inspiring and empowering [...]
Pluri Selected as CDMO by Remedy Cell for Cell-Derived Cell-Free Drug Manufacturing
14/03/2024
PluriCDMO™ will support Remedy Cell in the manufacture of RC-0315 product candidate for the treatment of Idiopathic Pulmonary Fibrosis (IPF) HAIFA, Israel, March 14, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq:PLUR) ( [...]
Aveanna Healthcare Holdings Announces Fourth Quarter 2023 Financial Results and 2024 Outlook
14/03/2024
Fourth Quarter Revenue was $478.8 million, a 6.1% increase over the prior year Gross margin increased 15.3% to $148.4 million, compared to Q4 2022 Fourth Quarter Net loss was $25.7 million, compared to net loss of $237. [...]
First Wave BioPharma Announces Completion of Business Combination with ImmunogenX, Adding Phase 3-Ready Latiglutenase to its Late-Stage GI-Focused Clinical Pipeline
14/03/2024
Latiglutenase is a potentially first-in-class oral biotherapeutic for the treatment of celiac disease James Sapirstein, Chairman and Chief Executive Officer, to continue leading First Wave BioPharma; Jack Syage, Ph.D., [...]
SMDG Announces Appointment of Industry Leader Dr. Zsuzsanna Devecseri to the Board of Directors
14/03/2024
Dr. Zsuzsanna Devecseri, MD, MBA, is the Global Head, Medical Affairs, Oncology, Novartis DURHAM, United Kingdom and CAMBRIDGE, United Kingdom, March 14, 2024 (GLOBE NEWSWIRE) -- S. M. Discovery Group (SMDG), a [...]
Atrogi Announces Positive Clinical Data from First-in-Class Insulin-Independent Treatment for Type 2 Diabetes
14/03/2024
All endpoints met for novel β₂-adrenoceptor agonist ATR-258 treating root cause of T2D SOLNA, Sweden, March 14, 2024 (GLOBE NEWSWIRE) -- Atrogi, a pioneering clinical-stage biotech company advancing treatments for [...]
IBEX Files Addendum to Management Proxy Circular for Sale of the Company at $1.45 Per Share
14/03/2024
MONTRÉAL, March 14, 2024 (GLOBE NEWSWIRE) -- IBEX Technologies Inc. (“ IBEX ” or the “ Company ”) (TSX Venture: IBT) announces that it has filed an addendum to its management proxy circular dated February 23, 2024 for [...]
Bayer and Aignostics to collaborate on next generation precision oncology
14/03/2024
Not intended for UK Media Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development, further strengthening Bayer’s precision oncology [...]
Amolyt Pharma Enters into Definitive Agreement to be Acquired by AstraZeneca
14/03/2024
AstraZeneca will acquire Amolyt Pharma for up to $1.05 billion in total consideration The transaction is expected to close in the third quarter of 2024 LYON, France and CAMBRIDGE, Mass., March 14, 2024 (GLOBE NEWSWIRE [...]
Amolyt Pharma conclut un accord définitif visant son acquisition par AstraZeneca
14/03/2024
AstraZeneca fera l’acquisition d’Amolyt Pharma pour un total pouvant atteindre 1,05 milliard de dollars. L’opération devrait être finalisée au troisième trimestre de 2024. Lyon (France) et Cambridge, Massachusetts, 14 [...]
Faron to Host Webcast to Discuss latest data from Phase 1 part of the BEXMAB Study of Bexmarilimab
14/03/2024
TURKU, Finland and BOSTON, March 14, 2024 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER approach to reprogramming myeloid [...]
Relation Therapeutics secures $35 million of new seed financing led by DCVC and co-lead NVentures, NVIDIA’s venture arm
14/03/2024
Relation Therap eutics secures $35 million of new seed financing led by DCVC and co-lead NVentures, NVIDIA’s venture arm London, March 2024 – Relation Therapeutics, a biotechnology company at the forefront of leveraging [...]
PanTera signs a second agreement for the supply of actinium-225
14/03/2024
PanTera’s continues to deploy its strategy to become a market leader into the production and distribution of Ac225 Mol, Belgium, March 14, 2024: PanTera, the Belgian radioisotope producer created as a joint venture by [...]
Anocca AB Licenses Gene Editing Technology from EmendoBio Inc.
14/03/2024
Enabling Technology Supports the Development of Anocca’s Deep Pipeline of TCR-T therapeutics NEW YORK and SÖDERTÄLJE, Sweden, March 14, 2024 (GLOBE NEWSWIRE) -- Anocca AB (Anocca), a leading T cell receptor-engineered T [...]
Addex to Present at the Bio-Europe Spring 2024 Conference
14/03/2024
Geneva, Switzerland, March 14, 2024 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, [...]
Santhera’s Partner Catalyst Pharmaceuticals Launches AGAMREE® (Vamorolone) in the United States
14/03/2024
AGAMREE® is U.S. FDA approved and now available in the United States for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older This follows the first commercial launch of AGAMREE in [...]

Pages